Literature DB >> 20877420

Chemotherapy: A new standard combination for recurrent ovarian cancer?

Robert C Bast, Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20877420      PMCID： PMC2956193          DOI： 10.1038/nrclinonc.2010.152

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

Authors:  Stephen A Cannistra
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

2.  A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection.

Authors:  A Vecchi; A Mantovani; A Tagliabue; F Spreafico
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

3.  Adriamycin induced immunomodulation: dependence upon time of administration.

Authors:  M J Ehrke; V Tomazic; K Ryoyama; S A Cohen; E Mihich
Journal:  Int J Immunopharmacol       Date:  1983

4.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

Authors:  Jacobus Pfisterer; Marie Plante; Ignace Vergote; Andreas du Bois; Hal Hirte; Angel J Lacave; Uwe Wagner; Anne Stähle; Gavin Stuart; Rainer Kimmig; Sigrid Olbricht; Tien Le; Janusz Emerich; Walther Kuhn; James Bentley; Christian Jackisch; Hans-Joachim Lück; Justine Rochon; Annamaria Hayden Zimmermann; Elizabeth Eisenhauer
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

5.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

6.  Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Authors:  Bradley J Monk; Thomas J Herzog; Stanley B Kaye; Carolyn N Krasner; Jan B Vermorken; Franco M Muggia; Eric Pujade-Lauraine; Alla S Lisyanskaya; Anatoly N Makhson; Janusz Rolski; Vera A Gorbounova; Prafull Ghatage; Mariusz Bidzinski; Keng Shen; Hextan Yuen-Sheung Ngan; Ignace B Vergote; Joo-Hyun Nam; Youn Choi Park; Claudia A Lebedinsky; Andrés M Poveda
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

Authors:  Robert C Bast; J Tate Thigpen; Susan G Arbuck; Karen Basen-Engquist; Laurie B Burke; Ralph Freedman; Sandra J Horning; Robert Ozols; Gordon J Rustin; David Spriggs; Lari B Wenzel; Richard Pazdur
Journal:  Gynecol Oncol       Date:  2007-11       Impact factor: 5.482

Review 8.  Hypersensitivity reactions to antineoplastic agents: an overview.

Authors:  Ekaterini Syrigou; Nektaria Makrilia; Ioanna Koti; Muhammad W Saif; Kostas N Syrigos
Journal:  Anticancer Drugs       Date:  2009-01       Impact factor: 2.248

9.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Authors:  M K B Parmar; J A Ledermann; N Colombo; A du Bois; J-F Delaloye; G B Kristensen; S Wheeler; A M Swart; W Qian; V Torri; I Floriani; G Jayson; A Lamont; C Tropé
Journal:  Lancet       Date:  2003-06-21       Impact factor: 79.321

10.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

Authors:  Maurie Markman; James Moon; Sharon Wilczynski; Ana Maria Lopez; Kendrith M Rowland; David P Michelin; Victor J Lanzotti; Garnet L Anderson; David S Alberts
Journal:  Gynecol Oncol       Date:  2009-12-30       Impact factor: 5.482
  10 in total
  2 in total

Review 1.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.

Authors:  Ignacio Romero; Robert C Bast
Journal:  Endocrinology       Date:  2012-03-13       Impact factor: 4.736

2.  Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors.

Authors:  Thanasak Sueblinvong; Rahel Ghebre; Yoshie Iizuka; Stefan E Pambuccian; Rachel Isaksson Vogel; Amy P N Skubitz; Martina Bazzaro
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.